Business Wire

Hanshow Showcases Retail Media and Store Intelligence at 2025 CGF Global Summit

19.6.2025 17:00:00 CEST | Business Wire | Press Release

Share

Hanshow, a global leader in digital retail solutions, underscored its leadership in AI, IoT, and Retail Media at the 2025 Global Summit of the Consumer Good Forum (CGF), held from June 11 to 13 at RAI Amsterdam. From an immersive ‘Future Store’ showcase in the I-Zone to moderating one of the Summit’s most anticipated panel discussions, Hanshow demonstrated how its integrated platform is driving the next wave of store transformation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619798164/en/

Inside the Future Store: Hanshow’s Real-Time Innovation at I-Zone

At Booth No.8 in the I-Zone, Hanshow presented an interactive showcase themed “Powering Your Future Store,” highlighting four core pillars of the future store: real-time pricing and shelf operations powered by ESLs; smart carts that enhance the shopping experience with autonomous navigation and seamless checkout; GenAI-enabled journeys offering contextual promotions and personalized assistance; and green technologies such as solar storage charging systems and in-store energy saving solutions.

Visitors explored how these technologies interoperate to elevate operational efficiency, enhance shopper experience, and advance sustainability. The showcase drew strong interest from retailers, tech leaders, and media, offering a vivid glimpse into how Hanshow is bridging digital and physical retail to deliver a unified, scalable transformation for digital and physical retail.

AI, IoT & RMNs: Driving the Next Wave of Retail Ecosystem Transformation

On June 12 in the Plenary Hall, a full house of industry attendees was eager to hear how AI, IoT, and Retail Media are reshaping the retail ecosystem. Philippe Brochard—Tech and Innovation Advisory Board Member at Hanshow and former Retail CEO, moderated the plenary panel “Redesigning Retail: AI, IoT and RMN – Empowering Tech-Driven Experiences and Sustainable Growth”, joined by:

  • Klaus Smets, Vice President, Hanshow Europe
  • Bas Komen, Director of Sales & Marketing for Retail Media, Albert Heijn
  • Bart Zoetmulder, Head of Market, Havas Media Netherlands

Philippe opened with four pivotal shifts: the rise of Retail Media Networks, the need for AI readiness, stores as digital platforms, and leadership in sustainable transformation.

Klaus Smets framed Hanshow as a key enabler connecting retailers, brands, and media agencies. He emphasized that the next frontier in Retail Media is in-store, where shelves, carts, and screens form a unified media network.

“By turning physical stores into data-driven, omnichannel touchpoints, we can synchronize availability, pricing, and messaging right where decisions are made,” he noted. Klaus added that Hanshow’s all-in-one platform, combining ESLs, smart carts, and digital signages—enables intelligent, media-capable stores powered by AI, backed by strong local service, and anchored in ESG principles.

Bas Komen detailed Albert Heijn’s Retail Media Services aim to build brands and drive conversion for CPG brands, built on insights and strategic partnerships. Bart Zoetmulder emphasized Havas’s shift to a tech-first agency model, leveraging real-time shopper data and ‘Havas Forecast’ to scale personalization.

The panel concluded that retail transformation requires collaboration across media, retail, and technology anchored in the store. Hanshow’s mission is to bridge these domains and deliver actionable, data-driven in-store experiences.

Shaping the Future: Smarter, Greener, and Closer to Clients

Hanshow will continue investing in IoT, AI, and communication technologies, —ESLs, digital signage, smart carts, and robots. The company is expanding local service capabilities across Europe, the Americas, and APAC to ensure faster deployment and agile response.

Committed to ESG-aligned innovation, Hanshow aims to reduce environmental impact, and create long-term value through deeper collaboration with global tech and regional partners.

“We’re not just building technology, we’re co-designing the digital roadmap for the next era of retail with our clients,” said Shiguo Hou, CEO of Hanshow. “Innovation must empower, not isolate.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20250619798164/en/

Contacts

info@hanshow.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye